Zelasudil is under clinical development by Redx Pharma and currently in Phase II for Idiopathic Pulmonary Fibrosis. According to GlobalData, Phase II drugs for Idiopathic Pulmonary Fibrosis have a 35% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Zelasudil’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Zelasudil (RXC-007) is under development for the treatment of pancreatic ductal adenocarcinoma (PDAC), fibrotic diseases like non-alcoholic steatohepatitis, idiopathic pulmonary fibrosis and interstitial lung diseases. It was under development for the treatment of diabetic nephropathy, acute kidney disease and chronic kidney disease. It is administered through oral route. The drug candidate acts by targeting Rho-associated protein kinase 2 (ROCK2). It is developed based on Redox switch technology.
Redx Pharma overview
Redx Pharma, formerly Redx Pharma is a drug discovery and development company that develops early stage and small molecule therapeutics. The company’s major pipeline products include RXC004, RXC007, RXC008, DDR, RXC006/AZD5055, JZP815, among other drug candidates. Its drug products are used for the treatment of pancreatic cancer, idiopathic pulmonary fibrosis (IPF), fibro stenotic crohn’s disease, oncology and fibrosis, and Fibrosis, Cancer-associated fibrosis. Redx Pharma’s redox switch is also used for delivering multiple development candidates over mechanistic approaches in the treatment of cancer. The company conducts research through its facilities in the UK. Redx Pharma is headquartered in Macclesfield, the UK.
For a complete picture of Zelasudil’s drug-specific PTSR and LoA scores, buy the report here.